Search 

Headquartered in Burlington, MA, for 40 years SEKISUI Diagnostics has been committed to helping improve the lives of patients by providing innovative medical diagnostics to physicians and laboratories. We continue to invest in the areas of diabetes, infectious disease, coagulation, diagnostic enzymes and automated systems, and have a leading position as a provider of rapid tests in the US and high throughput coagulation systems in Japan. Our workforce spans six sites located in four countries. We are a sister company to SEKISUI Medical in Japan, making us a worldwide company with R&D and Manufacturing facilities on three continents. We develop, manufacture, and supply billions of tests each year to the global healthcare market through our commercial networks and partners.

Our product lines include:

• Clinical chemistry reagents

• Coagulation reagents

• Point-of-care rapid tests and immunoassay system

• Enzymes and specialty biochemicals

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence's proprietary messenger RNAi GOLD™ Platform can be used to create siRNAs that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron loading anemias. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Takeda, among others

Sygnature Discovery - enabling success in drug discovery

Sygnature Discovery (www.sygnaturediscovery.com ) is a leading independent provider of integrated drug discovery resource and expertise.  Since 2011, 33 compounds discovered by Sygnature for clients have entered pre-clinical development and so far 17 of these have progressed to clinical trials (Phases I, II and III).

We add considerable value to our clients'​ research projects by providing intellectual input and drug discovery expertise to accelerate target validation, hit identification, hit-to-lead, lead optimisation and drug discovery programmes.  Sygnature's capabilities include medicinal chemistry, in vitro biology, computational chemistry and informatics, DMPK, and protein crystallography (via affiliate company Peak Proteins).  We can also provide pre-clinical experimental services support through our sister company RenaSci.

Sygnature Discovery operates a business whose primary focus is value creation for our clients, through the application of integrated drug discovery know-how and close working relationships.  We have built a team of over 400 staff including pharmaceutical industry-experienced research scientists (over 80% PhD qualified) with the ability to collaborate on an equal footing with our clients’ scientists to drive drug discovery projects towards the clinic.

In summary, Sygnature Discovery offers:

•    Target validation
•    Hit identification
•    Hit-to-lead
•    Lead optimisation
•    Integrated drug discovery programmes
•    Medicinal chemistry
•    In vitro biology (including biophysics and live cell imaging)
•    Computational chemistry
•    DMPK
•    Protein crystallography

SYNthesis is a chemistry-focussed, contract research organisation providing custom synthesis and medicinal chemistry services.
The company was established in 2007 and operates a unique, hybrid business model combining medicinal chemistry & project management expertise based in both Australia and the USA, with high quality synthetic chemistry based in China.
In addition to Melbourne (Australia) where SYNthesis med chem's global headquarters are located, the company also has operations in Shanghai & Suzhou (China) together with offices in the UK and USA.
SYNthesis currently employs over 250 chemists based in Australia, China & the USA.
Our medicinal chemists provide the design, innovation, creativity and problem solving expertise required to complement the skills & capabilities of the company's expert team of synthetic chemists based in China.
Our medicinal chemists are all experienced and highly skilled scientists with a track record of delivering clinical candidates, a passion for discovering new medicines and a comprehensive insight gained from managing more than 100 projects covering all phases of the pharmaceutical R&D process.
They also act as project managers for custom synthesis and medicinal chemistry projects.